LEADER 02957nam 2200433z- 450 001 9910617309103321 005 20231214133627.0 035 $a(CKB)5850000000095839 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92985 035 $a(EXLCZ)995850000000095839 100 $a20202210d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aLeukemia 210 $aBrisbane, Australia$cExon Publications$d2022 311 $a0-645-33207-0 330 $aLeukemia, the most common cancer in children, is a hematological malignancy caused by clonal proliferation of abnormal lymphoid or hematopoietic cells in the bone marrow and/or lymphoid system. Leukemias can be classified into many subtypes based on cell of origin, clinical, phenotypic, and genetic information. Tremendous advances have been made in the leukemia field during the last several decades. Our understanding of the biology of different types of leukemia has significantly improved through a huge amount of basic and clinical research. The application of advanced diagnostic technologies has led to the identification of not only new leukemia subtypes but also the clinical outcomes of all leukemias. One classic example is pediatric acute lymphoblast leukemia, the most common fatal disease in children, which has become a highly curable disease with a curable rate of over 80%. The book Leukemia, written by an international team has covered many of these achievements. It provides the most up-to-date information on important topics such as the new 5th Edition of the World Health Organization Classification of hematolymphoid tumors, prognostic and predictive biomarkers, minimal residual disease, pharmacogenomics, diagnostic use of flow cytometry, and gives updates on several interesting leukemia entities such as infant leukemia, hairy cell leukemia, acute myeloid leukemia with myelodysplasia-related changes, secondary acute myeloid leukemia, and myeloid/lymphoid neoplasms with PDGFRA rearrangement. This book will be of great value to a wide audience seeking information in the leukemia field either for clinical purposes or research purposes. 606 $aMJCL$2bicssc 610 $aleukemia 610 $ahematolymphoid tumors 610 $ainfant leukemia 610 $ahairy cell leukemia 610 $ameasurable residual disease in acute leukemia 610 $aacute myeloid leukemia with myelodysplasia related changes 610 $asecondary acute myeloid leukemia 610 $amyeloid/lymphoid neoplasms 610 $aPDGFRA rearrangement 610 $aleukemia pharmacogenomics 610 $aacute lymphoblastic leukemia 615 7$aMJCL 700 $aLi$b Weijie$4edt$01319276 702 $aLi$b Weijie$4oth 906 $aBOOK 912 $a9910617309103321 996 $aLeukemia$93033690 997 $aUNINA